Hingson Chun, MD
Cardiovascular Disease · Honolulu, HINPI 1891883468
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 71.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $5,498 and has fallen 69.0% since, to $1,706 in 2025. Among cardiovascular disease clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $91.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$16K
- Boehringer Ingelheim$2K
- Medtronic$2K
- E.r. Squibb & Sons, L.L.C.$941
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$707
- AstraZeneca$389
- plus $1K from 10 others
What the payments were for
- Consulting fees$11,35050%
- Travel & lodging$4902%
- Food & beverage$10,97448%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 84 | $16,299 |
| Boehringer Ingelheim | 72 | $1,810 |
| Medtronic(2 entities) | 53 | $1,575 |
| E.r. Squibb & Sons, L.L.C. | 9 | $941 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $707 |
| AstraZeneca | 4 | $389 |
| Abbott | 10 | $292 |
| Regeneron | 2 | $208 |
| Impulse Dynamics (USA) Inc. | 2 | $157 |
| Janssen Scientific Affairs, LLC | 1 | $136 |
| Novartis | 1 | $125 |
| Baxter Healthcare | 1 | $69 |
| Merck | 1 | $62 |
| Acist Medical Systems, Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$9,550
- RESONATE EL ICD VR$622
- CAMZYOS$535
- LifeVest$512
- SelectSecure$381
- JARDIANCE$255
- FARXIGA$249
- ACCOLADE SR$246
- WATCHMAN FLX$175
- Micra$172
- ARCTIC FRONT ADVANCE$168
- RESONATE$149
- PERCIVA ICD VR$138
- XARELTO$136
- AURORA EV-ICD MRI SURESCAN$132
- ENTRESTO$125
- Farapulse$125
- GENERAL TACHY$125
- ELIQUIS$120
- Fortify Assura, Ellipse ICD$120
How this compares
$22,828 in reported general payments places this provider in the 90th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 690 | $821,268 |
| EntrestoSacubitril/Valsartan | 229 | $328,986 |
| XareltoRivaroxaban | 146 | $193,578 |
| JardianceEmpagliflozin | 70 | $100,597 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 106 | $29,260 |
| Flecainide Acetate | 498 | $27,346 |
| VerquvoVericiguat | 11 | $23,050 |
| Repatha SureclickEvolocumab | 15 | $17,925 |
| Amiodarone Hcl | 505 | $11,131 |
| Metoprolol Succinate | 550 | $10,310 |
| Carvedilol ErCarvedilol Phosphate | 23 | $10,239 |
| Atorvastatin Calcium | 158 | $6,364 |
| Propafenone Hcl ErPropafenone Hcl | 32 | $5,682 |
| Propafenone Hcl | 82 | $5,163 |
| PradaxaDabigatran Etexilate Mesylate | 11 | $4,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $125 | $328,986229 claims |
| Boehringer IngelheimJardiance, Pradaxa | $1,810 | $105,33381 claims |
| MerckVerquvo | $62 | $23,05011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Honolulu
- Dipanjan BanerjeeHonolulu$331K
- Joana MagnoHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
- Nath LimpruttidhamHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.